Literature DB >> 15257866

Protection against stroke and dementia: an update on the latest clinical trial evidence.

Bryan Williams1.   

Abstract

Recent meta-analyses have examined the relationship between lowering blood pressure (BP) and reducing the risk for stroke and dementia. Studies have shown that drug therapy that successfully reduces systolic BP by only 10 mm Hg results in significant protection against stroke. Controversy exists regarding the most effective regimen, with supporters for the standards of diuretics and beta-blockers, or angiotensin-converting enzyme inhibitors and calcium-channel blockers, pitted against the increasing evidence of the effectiveness of angiotensin-receptor blockers or statins. Additionally, the most effective strategy for delivery of BP-reducing therapy is being examined, with some studies supporting use of standards for primary prevention of stroke and reserving the newer drugs for secondary prevention. Ultimately, however, all agree that for patients with the highest risk for cardiovascular and cerebrovascular complications, the strategy of intervention is immaterial, and drug therapy, including low-dose aspirin, is vital.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15257866     DOI: 10.1007/s11906-004-0026-4

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  33 in total

1.  Use of ramipril in preventing stroke: double blind randomised trial.

Authors:  Jackie Bosch; Salim Yusuf; Janice Pogue; Peter Sleight; Eva Lonn; Badrudin Rangoonwala; Richard Davies; Jan Ostergren; Jeff Probstfield
Journal:  BMJ       Date:  2002-03-23

2.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

3.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

Authors:  J A Staessen; R Fagard; L Thijs; H Celis; G G Arabidze; W H Birkenhäger; C J Bulpitt; P W de Leeuw; C T Dollery; A E Fletcher; F Forette; G Leonetti; C Nachev; E T O'Brien; J Rosenfeld; J L Rodicio; J Tuomilehto; A Zanchetti
Journal:  Lancet       Date:  1997-09-13       Impact factor: 79.321

4.  15-year longitudinal study of blood pressure and dementia.

Authors:  I Skoog; B Lernfelt; S Landahl; B Palmertz; L A Andreasson; L Nilsson; G Persson; A Odén; A Svanborg
Journal:  Lancet       Date:  1996-04-27       Impact factor: 79.321

5.  Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial.

Authors:  Henry R Black; William J Elliott; Gregory Grandits; Patricia Grambsch; Tracy Lucente; William B White; James D Neaton; Richard H Grimm; Lennart Hansson; Yves Lacourciere; James Muller; Peter Sleight; Michael A Weber; Gordon Williams; Janet Wittes; Alberto Zanchetti; Robert J Anders
Journal:  JAMA       Date:  2003 Apr 23-30       Impact factor: 56.272

6.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

7.  The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial.

Authors:  Hans Lithell; Lennart Hansson; Ingmar Skoog; Dag Elmfeldt; Albert Hofman; Bertil Olofsson; Peter Trenkwalder; Alberto Zanchetti
Journal:  J Hypertens       Date:  2003-05       Impact factor: 4.844

8.  A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.

Authors:  Carl J Pepine; Eileen M Handberg; Rhonda M Cooper-DeHoff; Ronald G Marks; Peter Kowey; Franz H Messerli; Giuseppe Mancia; José L Cangiano; David Garcia-Barreto; Matyas Keltai; Serap Erdine; Heather A Bristol; H Robert Kolb; George L Bakris; Jerome D Cohen; William W Parmley
Journal:  JAMA       Date:  2003-12-03       Impact factor: 56.272

9.  Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003.

Authors:  Jan A Staessen; Ji-Guang Wang; Lutgarde Thijs
Journal:  J Hypertens       Date:  2003-06       Impact factor: 4.844

10.  Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions.

Authors:  Rory Collins; Jane Armitage; Sarah Parish; Peter Sleight; Richard Peto
Journal:  Lancet       Date:  2004-03-06       Impact factor: 79.321

View more
  1 in total

1.  JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice.

Authors: 
Journal:  Heart       Date:  2005-12       Impact factor: 5.994

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.